IN2012DN02968A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02968A
IN2012DN02968A IN2968DEN2012A IN2012DN02968A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A IN 2968DEN2012 A IN2968DEN2012 A IN 2968DEN2012A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A
Authority
IN
India
Prior art keywords
present
relates
heterocyclic
schizophrenia
solvate
Prior art date
Application number
Other languages
English (en)
Inventor
Paul David Ratcliffe
Thomas Russell Clarkson
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of IN2012DN02968A publication Critical patent/IN2012DN02968A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN2968DEN2012 2009-10-13 2010-10-11 IN2012DN02968A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
IN2012DN02968A true IN2012DN02968A (pt) 2015-07-31

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2968DEN2012 IN2012DN02968A (pt) 2009-10-13 2010-10-11

Country Status (12)

Country Link
US (1) US8841289B2 (pt)
EP (1) EP2488520B1 (pt)
JP (1) JP2013507417A (pt)
KR (1) KR20120100913A (pt)
CN (1) CN102666540A (pt)
AU (1) AU2010305825A1 (pt)
BR (1) BR112012008518A2 (pt)
CA (1) CA2776835A1 (pt)
IN (1) IN2012DN02968A (pt)
MX (1) MX2012004289A (pt)
RU (1) RU2012119488A (pt)
WO (1) WO2011045258A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563232T3 (es) 2011-07-29 2016-03-11 Taisho Pharmaceutical Co., Ltd. Compuesto de amidina o sal del mismo
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2013175315A1 (en) * 2012-05-22 2013-11-28 King Abdullah Univesity Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's|disease and other neurodegenerative disorders
AU2014320149A1 (en) 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
PT3386591T (pt) 2015-12-09 2020-10-01 Cadent Therapeutics Inc Moduladores de recetores nmda heteroaromáticos e suas utilizações
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
EP3816160A4 (en) * 2018-06-27 2022-03-16 Reborna Biosciences, Inc. PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198188A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
MXPA03009650A (es) * 2001-04-20 2005-03-07 Vertex Pharma Derivados de 9-deazoguanidina como inhibidores de gsk-3.
WO2003062235A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
EP2385047B1 (en) * 2005-07-26 2013-05-29 Sanofi Piperidinyl-substituted isoquinolone derivatives
CA2663161C (en) * 2006-09-11 2014-10-28 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
DK2132194T3 (da) * 2006-12-27 2011-06-27 Sanofi Aventis Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer
JP2010229035A (ja) 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
BRPI0820259A2 (pt) * 2007-11-14 2015-06-16 Neurosearch As Derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, composição farmacêutica, uso do derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, e, método de tratamento, prevenção ou alívio de uma doença ou uma desordem ou uma condição de um corpo de animal vivo
KR20100114123A (ko) 2008-02-29 2010-10-22 테크노 코어 인터내셔널 가부시키가이샤 팩 전지의 충전 장치 및 팩 전지의 품질 판정 장치

Also Published As

Publication number Publication date
EP2488520A1 (en) 2012-08-22
WO2011045258A1 (en) 2011-04-21
RU2012119488A (ru) 2013-11-20
US20120208796A1 (en) 2012-08-16
KR20120100913A (ko) 2012-09-12
CN102666540A (zh) 2012-09-12
MX2012004289A (es) 2012-06-12
AU2010305825A1 (en) 2012-04-19
EP2488520B1 (en) 2015-09-02
US8841289B2 (en) 2014-09-23
BR112012008518A2 (pt) 2016-04-05
JP2013507417A (ja) 2013-03-04
CA2776835A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
IN2012DN02968A (pt)
WO2011051490A3 (en) Heterocyclic derivatives
IN2014DN03206A (pt)
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
WO2009050242A3 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
MX2014015158A (es) Derivados de piridinona y piridazinona.
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
WO2008023258A8 (en) Piperidine derivatives
MX2010002900A (es) Derivados heterociclicos triciclicos.
MX2010004686A (es) Derivados heterociclicos.
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
MX2010012189A (es) Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2011011618A (es) Agentes terapeuticos 713.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.